CD19-BCMA CAR-T
/ Air Force Medical University
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 27, 2026
Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy.
(PubMed, Med)
- P1 | "CD19/BCMA CAR-T cell therapy is safe and effective in refractory gMG without lymphodepletion, leading to systemic immune reset that warrants future investigations in larger clinical trials."
IO biomarker • Journal • CNS Disorders • Myasthenia Gravis
April 16, 2025
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Ting Chang, MD | Trial primary completion date: Mar 2025 ➔ Nov 2025
Trial primary completion date • CNS Disorders • Myasthenia Gravis
1 to 2
Of
2
Go to page
1